Dupixent Lawsuit Payout Per Person

Find Out If You Have a Case

Free, confidential review by Attorney Matthew T. Marin. Prefer to talk? Call (888) 348-2735.

Nobody can tell you today what the Dupixent lawsuit will pay per person, because no settlement program exists in MDL 3180 and no bellwether trial has produced a verdict. What can be explained honestly is how per-person payouts are built in pharmaceutical litigation — the tiers, the point systems, the deductions — so that when numbers do appear you can read them, and so you can recognize a lawyer who is guessing.

As of September 15, 2026: at least 36 member actions identified in MDL 3180. See the member-case ledger on the MDL 3180 tracker.

Is there a Dupixent settlement yet?

No. As of September 15, 2026 the litigation is in its earliest pretrial phase in MDL 3180; discovery is stayed under the court’s Initial Procedure Order No. 1 and no bellwether trials have been scheduled or held. Any website quoting an “average Dupixent settlement” is describing other litigations or inventing a number; our verdicts and settlements page lists what has actually been resolved.

How per-person payouts are usually structured in drug MDLs

When a mass-tort settlement is reached, it is almost never one amount split evenly. The typical structure is a settlement matrix: injury tiers set base amounts, and points adjust each patient’s award up or down for diagnosis severity and stage, treatment burden, age, duration of drug use before diagnosis, and the strength of the prescription and pathology evidence. A patient with biopsy-confirmed advanced-stage lymphoma after years of Dupixent use would be placed in a higher tier than a patient with an early-stage diagnosis and a short exposure.

What moves an individual patient up or down the matrix

• Diagnosis and stage: lymphoma type and stage at diagnosis; see qualifying lymphoma types.
• Treatment burden: chemotherapy, radiation, transplant, ongoing monitoring.
• Exposure: how long Dupixent was used before diagnosis, and for what indication.
• Economic loss: medical bills, lost wages, future care.
• Proof quality: pathology report, prescription records, and dermatology notes showing the eczema-to-lymphoma timeline; see evidence: what to save.
• Timing: claims filed inside the deadline carry full weight.

What is deducted before the patient is paid

From a gross award, the contingency fee, the case expenses set out in the engagement agreement, and any medical liens are paid before the patient receives the net amount. Medicare, Medicaid and private insurers that paid for cancer treatment may assert liens; resolving them is part of the lawyer’s job and the amounts vary by patient.

Bellwether verdicts vs. settlement per person

A bellwether verdict is a single jury’s decision in a single test case; it is not what everyone receives. Verdicts set negotiating ranges. If bellwethers favor patients, the defendants usually negotiate a global program with the tier structure above; if they favor defendants, values fall or cases are remanded for individual trials. Progress is tracked on the MDL 3180 tracker.

How to protect your place in a future payout

File inside your state’s deadline, keep every record that ties the diagnosis to the prescription history, and do not accept an early individual offer without counsel. Our settlement amounts page explains valuation in more depth; do I qualify covers eligibility.

Frequently asked questions